Treating GC in the Face of Dwindling Antibiotic Options – (2)

For GC antibiotics, the development path looks like a trip down the road less traveled, leading into some uncharted territory. Let’s take Melinta’s statement [1] at face value according to which the single 900 mg dose of delafloxacin failed because of “insufficient efficacy”. So, what then determines efficacy?  Delafloxacin’s MIC90 was Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (2)

Vancomycin vs TMP/SMX for MRSA – Not the Final Word

Vancomycin got a bad reputation since the early 90ies when it became clear that it was slow to provide clinical improvement and microbiologic cure in MRSA patients.  It was associated with prolonged bacteremia even when combined with rifampin [1].  And for MSSA, anti-staph penicillins like nafcillin were always the better choice. Then, Continue reading Vancomycin vs TMP/SMX for MRSA – Not the Final Word

Cattle and Pigs and Chickens, Oh Yeah!

When the Veterinary Feed Directive (VFD) Final Rule was announced earlier this month by FDA, the accompanying press release called it a ‘major step towards judicious antibiotic use’ in veterinary medicine [1]. There are several elements which look good, at least on paper: As prescribers of any and all antibiotics it Continue reading Cattle and Pigs and Chickens, Oh Yeah!